Transplantation & Cellular Therapy
Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Hematopoietic cell transplantation involves replacing unhealthy bone marrow with healthy stem cells in patients with hematologic disorders. In the growing field of non-transplant cellular therapies, including chimeric antigen receptor T-cell therapies, patient- or donor-derived cells are being explored for the treatment and potential cure of blood cancers.
Cecilia BrownTransplantation & Cellular Therapy | December 2, 2022
Post-transplant cyclophosphamide]-based GVHD prophylaxis mitigates the development of gastrointestinal GVHD.
Read More
Leah SherwoodTransplantation & Cellular Therapy | November 29, 2022
Children with R/R B-cell ALL who received co-administered CD19-and CD22-directed CAR-T therapy had a 99% CR.
Cecilia BrownTransplantation & Cellular Therapy | November 29, 2022
Allogeneic CAR T-cells had “encouraging safety and efficacy” in patients with CD7-positive hematologic malignancies.
Cecilia BrownTransplantation & Cellular Therapy | November 29, 2022
Axicabtagene ciloleucel led to higher response rates and higher toxicity rates than tisagenlecleucel in R/R DLBCL.
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
Allogeneic off-the-shelf CAR T-cells “showed evidence of antileukemic activity” in heavily pretreated patients...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
Certain genetic features in tumor and plasma samples from patients with LBCL are associated with poor CD19-directed CAR-T...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
CD19-directed CAR T-cell therapy led to a complete remission in approximately half of patients...
Leah SherwoodMyeloma | October 25, 2022
Health-related quality of life improved in patients with R/R MM following treatment with the CAR T-cell treatment...
Leah SherwoodTransplantation & Cellular Therapy | October 25, 2022
Researchers have recently identified bacterial proliferation on the skin as a factor associated with the development of...
Leah SherwoodMyeloproliferative Neoplasms | October 12, 2022
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Leah SherwoodTransplantation & Cellular Therapy | October 11, 2022
Dr. Lentzsch and Dr. Wong discuss the role of transplantation in newly diagnosed systemic light chain (AL) amyloidosis...
Leah SherwoodMeeting News | October 6, 2022
Autologous chimeric antigen receptor (CAR) T-cell therapies have shown
Leah SherwoodTransplantation & Cellular Therapy | October 6, 2022
Carlos de Lima, MD, stopped by the Blood Cancers Today booth at the 2022 SOHO Annual Meeting to give his advice...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
A conditioning regimen of clofarabine plus total body irradiation prior to allogeneic hematopoietic stem cell transplantation ...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
Researchers had not previously studied the long-term impact of omidubicel...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
New research suggests venetoclax-containing regimens with intensive treatment and allogeneic hematopoietic stem cell ...
Leah SherwoodMyeloma | September 30, 2022
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
Cecilia BrownTransplantation & Cellular Therapy | September 15, 2022
The combination led to an overall survival rate of nearly 75% in patients with BPDCN...
Advertisement
Editorial Board

Advertisement